Yelena Y. Janjigian

机构：Memorial Sloan Kettering Cancer Center, Cornell University · ORCID：0000-0002-5357-5858

发表论文 733 篇 · 总被引 39399 次 · h-index 69

代表论文

• Efficacy of CLDN18.2-Targeted Radiotheranostics in Patient-Derived Models of Gastric Cancer (2026 · Journal of Nuclear Medicine · 被引 1)
• First-line (1L) trastuzumab deruxtecan (T-DXd) with volrustomig and fluoropyrimidine in patients with HER2-low gastric cancer (GC), gastroesophageal junction adenocarcinoma (GEJA), or esophageal adenocarcinoma (EA): DESTINY-Gastric03 (DG-03) part 5. (2026 · Journal of Clinical Oncology · 被引 1)
• An open-label, randomized, multicenter, phase 3 study of trastuzumab deruxtecan (T-DXd) + chemotherapy (chemo) ± pembrolizumab (pembro) versus chemo + trastuzumab ± pembro in first-line metastatic HER2+ gastric or gastroesophageal junction (GEJ) cancer: DESTINY-Gastric05. (2026 · Journal of Clinical Oncology · 被引 1)
• CLARITY-Gastric 01: A randomized phase 3 study of sonesitatug vedotin (sone ve), a Claudin18.2 (CLDN18.2)-targeted antibody-drug conjugate, in second- or later-line (2L+) advanced gastric or gastroesophageal junction cancer (GC/GEJC). (2026 · Journal of Clinical Oncology · 被引 1)
• Spatial organisation of tumor-infiltrating B-cells informs immune checkpoint inhibitor response in Claudin 18.2-expressing gastric cancer (2026 · Clinical Cancer Research)
• Supplementary Table S5 from Molecular Lineages of Sporadic Mismatch Repair–Deficient Colorectal Cancer (2026)